Dynamiker Biotechnology(Tianjin) Co., Ltd.

With the wide application of broad-spectrum antibiotics, corticosteroid, immunosuppressant, anti-tumor drugs, as well as the prevalence of AIDS and the development of organ transplantation, the invasive fungal diseases (IFD), with a high mortality, is increasing and complicated. The invasive Aspergillosis (IA) is rapidly increasing. The susceptible population is mainly people who receive immunosuppressive therapy, such as hematopoietic stem cell transplantation patients, hematic malignant carcinoma patients, solid organ transplantation patients, bone marrow transplantation patients as well as long-term chemotherapy and corticosteroid therapy patients and severe AIDS patients.

The clinical symptom of IA is non-specific. There are no identical features in CT scan and X-ray. The difficulty of early diagnosis and timely treatment results in a high mortality of 60%~100% ^[1]. The presence of galactomannan antigen against Aspergillus indicates a prior Aspergillus infection.

Dynamiker Aspergillus Galactomannan Assay is based on competitive Enzyme-linked Immunosorbent Assay (ELISA). It is used for the quantitative detection of Aspergillus glactomannan antigen in human serum and bronchoalveolar lavage fluid (BAL), offering a diagnostic reference for Aspergillus infection. The kit is intended for professional use only.